Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML

References

• Redaelli A, Stephens JM, Brandt S, et al. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev. 2004;30(1):103–117.
   PubMed Web of Science ®Google Scholar
• Korol EE, Wang S, Johnston K, et al. Health-related quality of life of patients with acute myeloid leukemia: a systematic literature review. Oncol Ther. 2017;5(1):1–16.
   PubMed Web of Science ®Google Scholar
• Wiese M, Daver N. Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. Am J Manag Care. 2018;24:S347–S355.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an International Expert Panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697–712.
   PubMed Web of Science ®Google Scholar
• Bryant AL, Drier SW, Lee S, et al. A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia. Leuk Res. 2018;70:106–116.
   PubMed Web of Science ®Google Scholar
• Buckley SA, Kirtane K, Walter RB, et al. Patient-reported outcomes in acute myeloid leukemia: where are we now? Blood Rev. 2018;32(1):81–87.
   PubMed Web of Science ®Google Scholar
• Cannella L, Efficace F, Giesinger J. How should we assess patient-reported outcomes in the onco-hematology clinic? Curr Opin Support Palliat Care. 2018;12(4):522–529.
   PubMed Web of Science ®Google Scholar
• Nipp RD, Temel JS. Harnessing the power of patient-reported outcomes in oncology. Clin Cancer Res. 2018;24(8):1777–1779.
   PubMed Web of Science ®Google Scholar
• Tomaszewski EL, Fickley CE, Maddux L, et al. The patient perspective on living with acute myeloid leukemia. Oncol Ther. 2016;4(2):225–238.
   PubMedGoogle Scholar
• Lucioni C, Finelli C, Mazzi S, et al. Costs and quality of life in patients with myelodysplastic syndromes. Am J Blood Res. 2013;3:246–259.
   PubMedGoogle Scholar
• Szende A, Schaefer C, Goss TF, et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes. 2009;7:81.
   PubMed Web of Science ®Google Scholar
• Anatchkova M, Donelson SM, Skalicky AM, et al. Exploring the implementation of patient-reported outcome measures in cancer care: need for more real-world evidence results in the peer reviewed literature. J Patient Rep Outcomes. 2018;2(1):64.
   PubMedGoogle Scholar
• ClinicalTrials.gov. The American Society of Hematology (ASH) Research Registry: a multicenter research registry of patients with hematologic disease; 2019 [cited 2019 Dec 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT03535220
   Google Scholar
• Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014;32(18):1919–1926.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Kantarjian H, Faderl S, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34(6):752–756.
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335.
   PubMed Web of Science ®Google Scholar
• Smith CC, Lin K, Stecula A, et al. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia. 2015;29(12):2390–2392.
   PubMed Web of Science ®Google Scholar
• Efficace F, Gaidano G, Lo-Coco F. Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? Blood. 2017;130(7):859–866.
   PubMed Web of Science ®Google Scholar
• Mori M, Kaneko N, Ueno Y, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017;35(5):556–565.
   PubMed Web of Science ®Google Scholar
• Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017;129(2):257–260.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Shah MV, Crooks P, New MJ. Symptom and impact disturbance: findings from a qualitative assessment of patients with acute myeloid leukemia (AML). Value Health. 2018;21:S473–S474.
   Google Scholar
• Cella D, Jensen SE, Webster K, et al. Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) Questionnaire. Value Health. 2012;15(8):1051–1058.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736.
   PubMed Web of Science ®Google Scholar
• FACIT.Org. FACIT-Dyspnea Scoring Downloads [cited 2023 March 15]. Available from: https://www.facit.org/measures-scoring-downloads/facit-dyspnea-scoring-downloads
   Google Scholar
• Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186–1196.
   PubMed Web of Science ®Google Scholar
• FACIT.Org. FACT-Leu Scoring Downloads [cited 2023 March 15]. Available from: https://www.facit.org/measures-scoring-downloads/fact-leu-scoring-downloads
   Google Scholar
• PROMIS Dyspnea Scoring Manual; 2017 [cited 2023 March 15]. Available from: https://staging.healthmeasures.net/images/PROMIS/manuals/PROMIS_Dyspnea_Scoring_Manual.pdf
   Google Scholar
• EQ-5D User Guides; Version 3.0, September 2019 [cited 2023 March 15]. Available from: https://euroqol.org/publications/user-guides/
   Google Scholar
• Devlin NJ, Shah KK, Feng Y, et al. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, et al. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018;124(3):587–595.
   PubMed Web of Science ®Google Scholar
• Walsh LEH, Rider A, Piercy J, et al. Real-world impact of physician and patient discordance on health-related quality of life in US patients with acute myeloid leukemia. Oncol Ther. 2019;7(1):67–81.
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Sanger TM, Dube S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003;53(8):754–760.
   PubMed Web of Science ®Google Scholar
• Molenberghs G, Verbeke G. A review on linear mixed models for longitudinal data, possibly subject to dropout. Stat Model. 2001;1(4):235–269.
   Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579–584.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioural sciences. Second Edition Hillsdale (NJ): Lawrence Erlbaum Associates; Copyright 1988. [cited 2023 March 15]. Available from: http://www.utstat.toronto.edu/∼brunner/oldclass/378f16/readings/CohenPower.pdf
   Google Scholar
• Beer TM, Miller K, Tombal B, et al. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: exploratory analyses of AFFIRM and PREVAIL studies. Eur J Cancer. 2017;87:21–29.
   PubMed Web of Science ®Google Scholar
• Pandya BJ, Chen CC, Medeiros BC, et al. Economic and clinical burden of relapsed and/or refractory active treatment episodes in patients with acute myeloid leukemia (AML) in the USA: a retrospective analysis of a commercial payer database. Adv Ther. 2019;36(8):1922–1935.
   PubMed Web of Science ®Google Scholar